Mobidiag, A Hologic Company

Mobidiag, a Hologic company, is a biotechnology firm based in Finland and France that specializes in near-patient molecular diagnostic solutions for acute care conditions. The company develops and markets advanced diagnostic instruments and tests aimed at gastrointestinal infections, respiratory infections, antimicrobial resistance, healthcare-associated infections, and sepsis. Its key platforms, Amplidiag and Novodiag, provide rapid test results within 50 minutes to two hours, with Novodiag uniquely combining real-time PCR and microarray technologies for simultaneous identification of multiple pathogens from a single sample. Acquired by Hologic, Inc. in 2021, Mobidiag integrates its acute care molecular diagnostics into Hologic’s broader portfolio, enhancing its global reach and regulatory capabilities. The company primarily serves healthcare providers and clinical laboratories that require fast and accurate molecular diagnostic testing to improve patient outcomes in acute care settings. Mobidiag's solutions are designed to support timely diagnosis and management of infectious diseases, making them essential in hospital and clinical environments.

• Employees 66
• Founded 2000
• Annual Revenue $42000000
• Total Funding $74148125